https://gpcardio.org/en/The Global Primary Care Cardiovascular Networken https://gpcardio.org/en/2026-09-30_triumph-2/https://gpcardio.org/en/2026-09-30_triumph-2/Wed, 30 Sep 2026 12:00:00 +0200Presented at EASD 2026 in Milan and published simultaneously in The Lancet. TRIUMPH-2 randomised 1,152 adults with obesity or overweight (BMI 27 or higher, mean 38.2) and type 2 diabetes (mean HbA1c 7.7 percent) to once-weekly retatrutide 4, 9 or 12 mg or placebo for 80 weeks at 92 sites in eight countries. Body weight changed by -11.9, -16.8 and -18.8 percent versus -5.1 percent with placebo… https://gpcardio.org/en/2026-09-30_amylin-in-milan/https://gpcardio.org/en/2026-09-30_amylin-in-milan/Wed, 30 Sep 2026 12:00:00 +0200Amylin day at EASD 2026 in Milan. REIMAGINE 2 (Lancet Diabetes and Endocrinology) randomised 2,713 adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor (mean HbA1c 8.2 percent, BMI 25 or higher) to CagriSema 2.4/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, lower doses or placebo for 68 weeks. HbA1c fell by 1.91 versus 1.75 percentage points (difference -0.16, 95% CI… https://gpcardio.org/en/2026-09-29_acute-coronary-syndrome-in-kawasaki-disease-from-infancy-to-adulthood/https://gpcardio.org/en/2026-09-29_acute-coronary-syndrome-in-kawasaki-disease-from-infancy-to-adulthood/Tue, 29 Sep 2026 13:00:00 +0200This Circulation review addresses the growing population of Kawasaki disease survivors at risk for acute coronary syndrome, highlighting how KD-specific coronary pathology and thrombosis risk diverge from traditional atherosclerotic disease. It synthesizes current evidence on advanced coronary imaging, tailored revascularization strategies, and optimized antithrombotic regimens to guide… https://gpcardio.org/en/2026-09-29_heart-failure-with-a-preserved-ejection-fraction/https://gpcardio.org/en/2026-09-29_heart-failure-with-a-preserved-ejection-fraction/Tue, 29 Sep 2026 13:00:00 +0200This narrative review frames heart failure with preserved ejection fraction (HFpEF) as a systemic disease driven by the convergence of obesity, type 2 diabetes, and chronic kidney disease, which promote microvascular dysfunction, endothelial impairment, and myocardial fibrosis. It details how SGLT2 inhibitors, GLP-1 receptor agonists, dual incretin therapies, and (non-steroidal) mineralocorticoid… https://gpcardio.org/en/2026-09-29_transcend-t2d-1/https://gpcardio.org/en/2026-09-29_transcend-t2d-1/Tue, 29 Sep 2026 12:00:00 +0200Phase 3, double-blind trial in 537 adults with type 2 diabetes inadequately controlled on diet and exercise (mean HbA1c 7.9 percent, BMI 35.8, diabetes duration 2.5 years), randomised to once-weekly retatrutide 4, 9 or 12 mg or placebo for 40 weeks at 48 sites in the USA, Mexico and India. HbA1c fell by 1.69, 1.86 and 1.94 percentage points versus 0.81 with placebo (treatment differences -0.88 to… https://gpcardio.org/en/2026-09-27_ckm/https://gpcardio.org/en/2026-09-27_ckm/Sun, 27 Sep 2026 13:00:00 +0200The cardiovascular-kidney-metabolic (CKM) syndrome framework captures the continuum linking obesity, metabolic dysfunction, chronic kidney disease, and cardiovascular disease. Population data show that over 75% of adults meet criteria for at least stage 1 CKM, with a graded increase in cardiovascular mortality, heart failure hospitalizations, and kidney failure as stages advance. The newly… https://gpcardio.org/en/2026-09-27_survival-benefit-of-deceased-donor-kidney-transplantation-versus-continued-dialysis/https://gpcardio.org/en/2026-09-27_survival-benefit-of-deceased-donor-kidney-transplantation-versus-continued-dialysis/Sun, 27 Sep 2026 13:00:00 +0200An international target trial emulation involving 64,036 patients on dialysis demonstrates that deceased donor kidney transplantation using standard criteria donors (SCD) significantly improves five-year survival across all age groups and comorbidity profiles. However, the survival advantage diminishes with expanding donor criteria and increasing recipient age; among 75-year-olds receiving an… https://gpcardio.org/en/2026-09-27_perioperative-management-of-sglt2-inhibitors/https://gpcardio.org/en/2026-09-27_perioperative-management-of-sglt2-inhibitors/Sun, 27 Sep 2026 13:00:00 +0200This review addresses the perioperative management of SGLT2 inhibitors in patients with heart failure, chronic kidney disease, or type 2 diabetes. While guidelines typically recommend withholding the drug 3–4 days before elective surgery to prevent euglycaemic diabetic ketoacidosis, emerging evidence highlights competing risks: continuing therapy may reduce acute kidney injury and short-term… https://gpcardio.org/en/2026-09-27_optimising-management-with-sglt-2i-based-strategies-in-primary-care/https://gpcardio.org/en/2026-09-27_optimising-management-with-sglt-2i-based-strategies-in-primary-care/Sun, 27 Sep 2026 00:00:00 +0200In this short video series, Prof Richard Hobbs (University of Oxford, Oxford, UK), Dr Sarah Davies (Woodlands Medical Centre, Cardiff, UK) and Dr Ileana Piña (Thomas Jefferson University, Philadelphia, US) explore practical strategies for improving cardiorenal risk management in patients with chronic kidney disease (CKD), with and without diabetes. https://gpcardio.org/en/2026-09-27_the-foundation-of-cardiorenal-protection-what-the-guidelines-say/https://gpcardio.org/en/2026-09-27_the-foundation-of-cardiorenal-protection-what-the-guidelines-say/Sun, 27 Sep 2026 00:00:00 +0200 https://gpcardio.org/en/2026-09-27_cardiorenal-risk-management-at-the-interface-of-primary-care-and-cardiology/https://gpcardio.org/en/2026-09-27_cardiorenal-risk-management-at-the-interface-of-primary-care-and-cardiology/Sun, 27 Sep 2026 00:00:00 +0200In this short video series, Prof Richard Hobbs (University of Oxford, Oxford, UK), Dr Sarah Davies (Woodlands Medical Centre, Cardiff, UK) and Dr Ileana Piña (Thomas Jefferson University, Philadelphia, US) explore practical strategies for improving cardiorenal risk management in patients with chronic kidney disease (CKD), with and without diabetes. https://gpcardio.org/en/2026-09-26_eu-screening-week-know-your-numbers-campaign/https://gpcardio.org/en/2026-09-26_eu-screening-week-know-your-numbers-campaign/Sat, 26 Sep 2026 00:00:00 +0200EU Screening Week is a European prevention initiative taking place from 28 September to 4 October, as part of the wider Know Your Numbers campaign. https://gpcardio.org/en/2026-09-25_women-s-kidney-health-in-focus/https://gpcardio.org/en/2026-09-25_women-s-kidney-health-in-focus/Fri, 25 Sep 2026 13:00:00 +0200The American Heart Association has released a scientific statement highlighting sex-specific differences in chronic kidney disease (CKD), emphasizing biological factors, underrepresentation in clinical trials, and the strong link to cardiovascular mortality. The document underscores how hormonal changes, pregnancy complications, and menopause influence renal progression and cardiorenal risk… https://gpcardio.org/en/2026-09-25_glucosuria-as-a-marker-of-adherence-to-sodium-glucose-cotransporter-2-inhibitors-and-clinical-outcomes-in-real-world-practice/https://gpcardio.org/en/2026-09-25_glucosuria-as-a-marker-of-adherence-to-sodium-glucose-cotransporter-2-inhibitors-and-clinical-outcomes-in-real-world-practice/Fri, 25 Sep 2026 13:00:00 +0200A real-world cohort study of nearly 46,000 patients evaluated whether glucosuria on routine urinalysis serves as a practical proxy for adherence to SGLT2 inhibitors. After inverse probability weighting, patients with glucosuria (≥2+) had significantly lower risks of all-cause mortality (HR 0.78), heart failure hospitalization (HR 0.87), and end-stage kidney disease (HR 0.73) compared to those… https://gpcardio.org/en/2026-09-23_a-synopsis-of-the-2025-u-s-department-of-veterans-affairs-and-u-s-department-of-defense-clinical-practice-guideline-for-lipid-management-for-cardiovascular-disease-risk-reduction/https://gpcardio.org/en/2026-09-23_a-synopsis-of-the-2025-u-s-department-of-veterans-affairs-and-u-s-department-of-defense-clinical-practice-guideline-for-lipid-management-for-cardiovascular-disease-risk-reduction/Wed, 23 Sep 2026 13:00:00 +0200The 2025 VA/DoD clinical practice guideline on lipid management introduces updated cardiovascular risk assessment tools, including the PREVENT calculator, one-time lipoprotein(a) testing, and coronary artery calcium scoring for risk refinement. It recommends moderate-intensity statins for primary prevention in intermediate-to-high risk patients and HIV-positive adults, while advocating… https://gpcardio.org/en/2026-09-20_postpartum-hypertension/https://gpcardio.org/en/2026-09-20_postpartum-hypertension/Sun, 20 Sep 2026 13:00:00 +0200This narrative review highlights the substantial long-term cardiovascular risk associated with hypertensive disorders of pregnancy and positions the postpartum period as a critical window for preventive care. Emerging evidence supports tighter blood pressure targets, expanded remote monitoring, and multidisciplinary care pathways to improve detection and reduce readmissions. Clinicians should… https://gpcardio.org/en/2026-09-19_catheter-ablation-for-symptomatic-atrial-fibrillation-pvi-sham-af/https://gpcardio.org/en/2026-09-19_catheter-ablation-for-symptomatic-atrial-fibrillation-pvi-sham-af/Sat, 19 Sep 2026 13:00:00 +0200In the double-blind, sham-controlled PVI-SHAM-AF trial, 262 patients with symptomatic paroxysmal or persistent atrial fibrillation were randomised to catheter ablation or a sham procedure. At six months, ablation did not significantly improve atrial fibrillation-related quality of life compared with sham (Hodges-Lehmann estimate 2.6; 95% CI -2.7 to 8.0; p=0.36). Published in The Lancet, these… https://gpcardio.org/en/2026-09-19_stroke-insights-connecting-science-and-lived-experience/https://gpcardio.org/en/2026-09-19_stroke-insights-connecting-science-and-lived-experience/Sat, 19 Sep 2026 00:00:00 +0200Stroke Insights is a new initiative developed by the European Stroke Organisation (ESO) and SHINE Global Stroke Collaboration https://gpcardio.org/en/2026-09-17_impact-of-nonsteroidal-mineralocorticoid-receptor-antagonism-on-cardiorenal-outcomes-in-diabetic-kidney-disease/https://gpcardio.org/en/2026-09-17_impact-of-nonsteroidal-mineralocorticoid-receptor-antagonism-on-cardiorenal-outcomes-in-diabetic-kidney-disease/Thu, 17 Sep 2026 13:00:00 +0200A systematic review of pooled analyses from the FIDELITY programme demonstrates that finerenone significantly reduces composite renal and cardiovascular outcomes in patients with diabetic kidney disease (HR 0.77 and 0.86, respectively). Over three years, absolute risk reductions were approximately 1.6% to 1.7%, accompanied by reduced albuminuria and a slower decline in eGFR. Although… https://gpcardio.org/en/2026-09-16_device-detected-atrial-fibrillation-after-artesia-and-noah-afnet-6/https://gpcardio.org/en/2026-09-16_device-detected-atrial-fibrillation-after-artesia-and-noah-afnet-6/Wed, 16 Sep 2026 13:00:00 +0200This narrative review synthesizes evidence from the ARTESiA and NOAH-AFNET 6 trials regarding anticoagulation for device-detected atrial high-rate episodes and subclinical atrial fibrillation. While DOACs significantly reduce ischemic stroke risk, they increase major bleeding; the annual untreated stroke rate remains low at approximately 1%. Clinical decisions should therefore prioritize absolute… https://gpcardio.org/en/2026-09-15_the-2025-aha-acc-hypertension-guidelines/https://gpcardio.org/en/2026-09-15_the-2025-aha-acc-hypertension-guidelines/Tue, 15 Sep 2026 13:00:00 +0200The 2025 AHA/ACC hypertension guideline maintains the <130/80 mmHg treatment goal but adopts a strictly risk-based approach, recommending pharmacotherapy for stage-1 hypertension once the 10-year ASCVD risk reaches 7.5%. Key updates include the race-free PREVENT risk calculator, broader primary aldosteronism screening, routine urine albumin-to-creatinine ratio testing, and cautious incorporation… https://gpcardio.org/en/2026-09-13_efficacy-and-safety-of-canagliflozin-are-consistent-across-polypharmacy-burden-in-ckd/https://gpcardio.org/en/2026-09-13_efficacy-and-safety-of-canagliflozin-are-consistent-across-polypharmacy-burden-in-ckd/Sun, 13 Sep 2026 13:00:00 +0200A post-hoc analysis of the CREDENCE trial found that canagliflozin maintains consistent efficacy and safety across varying levels of polypharmacy in patients with type 2 diabetes and chronic kidney disease (CKD). While relative risk reductions for kidney and cardiovascular outcomes were similar regardless of medication burden, absolute risk reductions were substantially greater in patients taking… https://gpcardio.org/en/2026-09-12_inflammation-as-a-therapeutic-target-to-improve-kidney-and-cardiovascular-outcomes/https://gpcardio.org/en/2026-09-12_inflammation-as-a-therapeutic-target-to-improve-kidney-and-cardiovascular-outcomes/Sat, 12 Sep 2026 13:00:00 +0200Chronic kidney disease is driven by a pro-inflammatory state that accelerates both renal decline and major cardiovascular events. This review outlines key inflammatory pathways and highlights potential therapeutic targets, ranging from investigational agents (ASK1, JAK, and IL-1β/IL-6 inhibitors) to established cardiorenal medications with proven anti-inflammatory effects, including SGLT2… https://gpcardio.org/en/2026-09-11_from-insulin-resistance-to-incretin-receptor-agonism-in-the-prevention-of-type-2-diabetes-mellitus-in-obese-individuals/https://gpcardio.org/en/2026-09-11_from-insulin-resistance-to-incretin-receptor-agonism-in-the-prevention-of-type-2-diabetes-mellitus-in-obese-individuals/Fri, 11 Sep 2026 13:00:00 +0200This narrative review evaluates pharmacological strategies for preventing type 2 diabetes in individuals with obesity and insulin resistance. While metformin retains the strongest long-term evidence for diabetes prevention, GLP-1 receptor agonists and tirzepatide demonstrate that substantial weight loss significantly delays progression to overt diabetes. SGLT2 inhibitors offer proven… https://gpcardio.org/en/2026-09-11_glucagon-like-peptide-1-receptor-agonists-for-obstructive-sleep-apnea/https://gpcardio.org/en/2026-09-11_glucagon-like-peptide-1-receptor-agonists-for-obstructive-sleep-apnea/Fri, 11 Sep 2026 13:00:00 +0200A recent narrative review and phase 3 trial data (SURMOUNT-OSA) demonstrate that GLP-1 receptor agonists, including tirzepatide, reduce the apnea-hypopnea index by 20 to 24 events per hour in adults with obesity and obstructive sleep apnea. Remission rates reach 42% to 50% (AHI <5 or <15 without symptoms), primarily driven by weight loss and reduced upper airway adipose tissue. While efficacy… https://gpcardio.org/en/2026-09-09_dipeptidyl-peptidase-4-inhibitors-associated-heart-failure-events-in-adult-patients-with-type-2-diabetes-mellitus-treated-with-dipeptidyl-peptidase-4-inhibitors/https://gpcardio.org/en/2026-09-09_dipeptidyl-peptidase-4-inhibitors-associated-heart-failure-events-in-adult-patients-with-type-2-diabetes-mellitus-treated-with-dipeptidyl-peptidase-4-inhibitors/Wed, 09 Sep 2026 13:00:00 +0200A systematic review and meta-analysis of 29 randomised controlled trials (n=67,873) evaluated the association between DPP-4 inhibitors and heart failure in adults with type 2 diabetes. Overall, DPP-4 inhibitor use was not significantly associated with an increased risk of heart failure (RR 1.06; 95% CI 0.94–1.12), although subgroup analysis identified a significant risk increase specifically with… https://gpcardio.org/en/2026-09-09_adverse-pregnancy-outcomes-and-long-term-cardiovascular-risk/https://gpcardio.org/en/2026-09-09_adverse-pregnancy-outcomes-and-long-term-cardiovascular-risk/Wed, 09 Sep 2026 13:00:00 +0200A narrative review in the European Heart Journal highlights that adverse pregnancy outcomes, including hypertensive disorders, gestational diabetes, and preterm birth, serve as early markers of underlying cardiometabolic dysfunction rather than isolated obstetric events. Women with these complications face a significantly elevated long-term risk of coronary artery disease, heart failure, chronic… https://gpcardio.org/en/2026-09-08_performance-of-estimated-glomerular-filtration-rate-equations-across-ethnic-groups-in-the-aim-ckd-uk-cohort/https://gpcardio.org/en/2026-09-08_performance-of-estimated-glomerular-filtration-rate-equations-across-ethnic-groups-in-the-aim-ckd-uk-cohort/Tue, 08 Sep 2026 13:00:00 +0200A multicentre cross-sectional study of 15,879 adults in the UK compared five creatinine-based eGFR equations against measured GFR. The Lund-Malmö Revised (LMR) and EKFC equations demonstrated the highest accuracy and least bias, particularly in South Asian, young, and low-BMI populations. Using outdated equations could inappropriately exclude 29% to 52% of eligible patients from SGLT2 inhibitor… https://gpcardio.org/en/2026-09-07_mapping-the-modifiable-exposome-for-ischemic-stroke/https://gpcardio.org/en/2026-09-07_mapping-the-modifiable-exposome-for-ischemic-stroke/Mon, 07 Sep 2026 13:00:00 +0200A large prospective cohort study of nearly 500,000 UK Biobank participants, combined with bidirectional Mendelian randomization, evaluated 323 modifiable risk factors for ischemic stroke. Eighteen factors demonstrated robust causal links, and a moderate one-third reduction in overall modifiable risk exposure was estimated to prevent 68.2% of strokes. These findings suggest that achievable… https://gpcardio.org/en/2026-09-07_ckd-new-esc-guidelines-every-patient-with-heart-disease-should-now-be-tested-for-kidney-disease/https://gpcardio.org/en/2026-09-07_ckd-new-esc-guidelines-every-patient-with-heart-disease-should-now-be-tested-for-kidney-disease/Mon, 07 Sep 2026 00:00:00 +0200For the first time, the European Society of Cardiology (ESC) has issued dedicated guidelines on managing the overlap between cardiovascular disease (CVD) and chronic kidney disease (CKD). Developed jointly with the European Renal Association, the guidelines were released ahead of ESC Congress 2026 and mark a significant shift in how GPs and cardiologists should approach at-risk patients. https://gpcardio.org/en/2026-09-05_complications-of-transcatheter-aortic-valve-replacement/https://gpcardio.org/en/2026-09-05_complications-of-transcatheter-aortic-valve-replacement/Sat, 05 Sep 2026 13:00:00 +0200This narrative review outlines contemporary strategies for preventing, recognizing, and managing major complications following transcatheter aortic valve replacement (TAVR). It emphasizes the critical role of multidetector CT for anatomical planning, including assessment of annular/LVOT calcium, coronary obstruction risk, and vascular access, while detailing the management of key procedural… https://gpcardio.org/en/2026-09-03_paediatric-to-adult-transition-in-inherited-arrhythmia-syndromes/https://gpcardio.org/en/2026-09-03_paediatric-to-adult-transition-in-inherited-arrhythmia-syndromes/Thu, 03 Sep 2026 13:00:00 +0200This European Heart Journal review addresses the frequent loss to follow-up and care gaps when transitioning patients with inherited arrhythmia syndromes (LQTS, CPVT, Brugada) from paediatric to adult services. It proposes a pragmatic pathway beginning in early adolescence, utilising a patient-held health passport and one of three transfer models (joint clinic, staged overlap, or virtual… https://gpcardio.org/en/2026-09-02_wearable-wrist-watch-type-cuff-oscillometric-blood-pressure-monitors/https://gpcardio.org/en/2026-09-02_wearable-wrist-watch-type-cuff-oscillometric-blood-pressure-monitors/Wed, 02 Sep 2026 13:00:00 +0200The European Society of Hypertension has issued a consensus statement on wearable wristwatch cuff oscillometric blood pressure monitors. A systematic review identified only two devices (Omron HeartGuide and Huawei Watch D/D2) meeting strict validation standards, with acceptable static accuracy but limited data on 24-hour ambulatory use, sleep BP, and special populations. While these wearables… https://gpcardio.org/en/2026-09-02_glucagon-like-peptide-1-receptor-agonists-mortality-and-cardiovascular-outcomes-in-serious-mental-illness/https://gpcardio.org/en/2026-09-02_glucagon-like-peptide-1-receptor-agonists-mortality-and-cardiovascular-outcomes-in-serious-mental-illness/Wed, 02 Sep 2026 13:00:00 +0200In a large retrospective target trial emulation using electronic health records, initiation of GLP-1 receptor agonists versus SGLT2 inhibitors was associated with significantly lower 4-year all-cause mortality (HR 0.76; 4.91% vs 6.45%) and reduced major adverse cardiovascular events in adults with serious mental illness. Among patients with coexisting type 2 diabetes, semaglutide specifically… https://gpcardio.org/en/2026-09-01_risk-guided-screening-for-atrial-fibrillation-using-electronic-health-records/https://gpcardio.org/en/2026-09-01_risk-guided-screening-for-atrial-fibrillation-using-electronic-health-records/Tue, 01 Sep 2026 13:00:00 +0200Researchers developed and externally validated FIND-AF 2.0, a machine learning model using electronic health records to identify patients at high risk of developing atrial fibrillation (AF). In a prospective screening study of 1,923 adults, AF was detected in 4.5% of high-risk participants compared to 0.6% of low-risk individuals (OR 8.46; P<0.001), outperforming conventional risk scores like… https://gpcardio.org/en/2026-09-01_incidence-and-predictors-of-extracranial-bleeding-on-oral-anticoagulants-for-stroke-prevention-in-patients-with-atrial-fibrillation/https://gpcardio.org/en/2026-09-01_incidence-and-predictors-of-extracranial-bleeding-on-oral-anticoagulants-for-stroke-prevention-in-patients-with-atrial-fibrillation/Tue, 01 Sep 2026 13:00:00 +0200A pooled analysis of five pivotal randomized trials (COMBINE-AF; n=73,737) demonstrates that extracranial bleeding occurs in 26% of patients with atrial fibrillation on oral anticoagulants over a mean follow-up of nearly two years, translating to 7.6 events per 100 person-years. Major extracranial bleeds account for 7% of cases, while clinically relevant non-major bleeds make up 19%, with… https://gpcardio.org/en/2026-08-30_walking-a-tightrope/https://gpcardio.org/en/2026-08-30_walking-a-tightrope/Sun, 30 Aug 2026 13:00:00 +0200A systematic review and meta-analysis evaluated direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation and a history of intracranial haemorrhage. Based on five observational studies, DOACs were associated with a lower risk of recurrent intracranial haemorrhage (HR 0.65) and ischaemic stroke (HR 0.80), although evidence certainty ranged from… https://gpcardio.org/en/2026-08-30_acasa-tavi/https://gpcardio.org/en/2026-08-30_acasa-tavi/Sun, 30 Aug 2026 12:00:00 +0200Investigator-initiated head-to-head trial in three Norwegian hospitals: 360 patients aged 65 to 80 after TAVI randomised to DOAC monotherapy (apixaban, edoxaban or rivaroxaban) or aspirin monotherapy. Hypo-attenuated leaflet thickening at 12 months 17.2 versus 32.6 percent (RR 0.55, p=0.004); safety composite of VARC-3 bleeding, thromboembolism or death 7.5 versus 10.6 percent (non-inferior)… https://gpcardio.org/en/2026-08-30_the-clinician-as-patient/https://gpcardio.org/en/2026-08-30_the-clinician-as-patient/Sun, 30 Aug 2026 12:00:00 +0200Cross-sectional health check of more than 1,300 healthcare professionals at ESC Congress 2025 with age- and sex-matched general-population controls. Excess weight 46.8 percent, hypertension 23.2 percent, high cholesterol 22.7 percent; subclinical atherosclerosis in about 20 percent without known disease; only 27.6 percent of eligible professionals on blood pressure medication versus 46.5 percent… https://gpcardio.org/en/2026-08-30_tric-i-hf/https://gpcardio.org/en/2026-08-30_tric-i-hf/Sun, 30 Aug 2026 12:00:00 +0200The hard-endpoint trial the tricuspid field lacked: 360 patients (mean 80 years, 56 percent women) with heart failure and severe tricuspid regurgitation in 29 German centres, randomised 2:1 to transcatheter edge-to-edge repair (98 percent) plus medical therapy or medical therapy alone. One-year hierarchical endpoint win ratio 2.42 (95% CI 1.76 to 3.33, p under 0.001); freedom from death or HF…